Moderna(MRNA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates Reports third quarter revenues of $1.9 billion, GAAP net income of$13 million and GAAP EPS of $0.03 Achieves year-to-date product sales of$2.2 billion; reiterates 2024 expected product sales of $3.0 to$3.5 billion Initiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenza Announces expansion of its Executive Committee CAMBRIDGE, MA / ACCES ...